Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ciphergen Biosystems(CIPH): -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (31)	2/15/2002 12:31:52 PM
From: michael97123	Respond to of 510

Tuck, Cant listen at work. Everything i ever buy goes down intially. I bought yesterday thru Knight. Always get ripped off there. New to biotech and new to low volume stuff. I was joking about patience. So cancel the long weekend and listen to the call already. <g> Have a good one. I will look at this board again next week. BTW found nothing on yahoo. If i do i will post. mike

To: tuck who wrote (31)	2/16/2002 6:01:43 PM
From: michael97123	Respond to of 510

Tuck, Bought a new car today. Buyers remorse again. Below from yahoo. mike Earnings Conference Call by: Biotech_Vendor Long-Term Sentiment: Strong Buy 02/16/02 03:58 pm Msg: 577 of 577 Listened today, good call. No comments on suit. Reiterated the importance of the announced collab with Aaron Diamond AIDS Res Ctr and initial early results. Various collabs being initiated and new ones being discussed, but no specific mentions. 2002 projected sales $38M -> $40M. Diverse sources of revenue and revenue growth. Latest Revs: 60% equipment, 35% consumables, 5% services. Clinical proteomics market size: approx. 25,000 labs based in universities, university medical research centers and toxicology facilities in big pharma companies. This is the ProteinChip® System key market. Already installed in 13 of 40 NCI Cancer Ctrs + 28 other major cancer facilities worldwide. Have presented and marketed to 27 futher major cancer centers WW. Core research market acceptance is growing. Single marker diagnostics and predictive paradigm shifting to the multiple marker paradigm as demonstrated in the ovarian cancer study. Patents increasing in key areas: 9 issued, 33 patents pending. SG Cowen on the call asked questions as did a reporter from Bio Array News. Nothing from UBS Warburg. IMHO, if you want to invest, YOU need to listen. YOU are responsible for your Due Diligence."